Mortality in adults with chronic hepatitis B infection in the United States: a population‐based study
Open Access
- 20 May 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (2), 382-389
- https://doi.org/10.1111/apt.15803
Abstract
Background Chronic hepatitis B infection is an important contributor to mortality in the United States, yet impact of available and effective oral antivirals on mortality among infected individuals is unknown. Aims To compare risks and predictors of mortality in a recent time period between those with chronic, prior and no hepatitis B infection. Methods This is a population‐based cohort study of National Health and Nutrition Examination Surveys participants between 1999 and 2014 linked to National Death Index data. Adults aged 20 years or older with hepatitis B serologic testing were included. Outcomes of all‐cause and liver‐related mortality were evaluated using Cox regression. Results Of 39 206 participants, 192 (0.5%) had chronic and 2694 (6.9%) had prior hepatitis B infection. The all‐cause age/sex‐standardised mortality rates for chronic, prior and uninfected were 21.4, 15.1 and 11.8 per 1000 person‐years respectively. Liver‐related mortality occurred at respective rates of 4.1, 0.3 and 0.1 per 1000 person‐years. In multivariable analyses, those with chronic infection had 1.9‐fold (95% CI 1.1‐3.3) increased hazard of all‐cause mortality and 13.3‐fold (95% CI 3.9‐45.5) increased hazard of liver‐related mortality compared to uninfected. Predictors of all‐cause mortality among chronic infection included heavy alcohol use (HR 18.3, 95% CI 3.3‐100.6) and higher alanine aminotransferase (HR 1.02, 95% CI 1.00‐1.03). Conclusions Mortality among adults living with chronic hepatitis B infection still exceeds that of uninfected despite availability of improved therapeutics. Identification of chronic infection, initiation of treatment among eligible and modulation of co‐factors for disease progression are needed to improve survival.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 5T32DK060414-14)
- Liver Center, University of California, San Francisco (P30 DK026743)
This publication has 30 references indexed in Scilit:
- Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs LamivudineGastroenterology, 2014
- Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosisJournal of Hepatology, 2013
- The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007Annals of Internal Medicine, 2012
- Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of originHepatology, 2011
- Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessmentHepatology, 2007
- Risk and Predictors of Mortality Associated With Chronic Hepatitis B InfectionClinical Gastroenterology and Hepatology, 2007
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Cofactors associated with liver disease mortality in an HBsAg‐positive Mediterranean cohort: 20 years of follow‐upInternational Journal of Cancer, 2006
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelPublished by American Medical Association (AMA) ,2006
- Hepatitis B Virus Infection — Natural History and Clinical ConsequencesThe New England Journal of Medicine, 2004